Please enable JavaScript to continue using this application.

Compare $IDYA vs $PBLS | Chartloom

Compare

$IDYA vs $PBLS

IDEAYA Biosciences Inc · Parabilis Medicines Inc

IDYA

IDEAYA Biosciences Inc

PBLS

Parabilis Medicines Inc

Compare $IDYA vs $PBLS

Comparing IDEAYA Biosciences Inc and Parabilis Medicines Inc

IDYAIDEAYA Biosciences Inc

PBLSParabilis Medicines Inc

IDYAIDEAYA Biosciences Inc

Market cap

$3.43B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

59.38x

Rev growth (TTM)

3244.7%

YTD performance

6.7%

52W performance

34.5%

FCF yield

-3.3%

PBLSParabilis Medicines Inc

Market cap

$3.20B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

581.53x

Rev growth (TTM)

—

YTD performance

-13.0%

52W performance

-13.0%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IDYA

PBLS

Detailed metrics comparison

IDYA

IDEAYA Biosciences Inc

PBLS

Parabilis Medicines Inc

Market Cap

IDYA$3.43B

PBLS$3.20B

Enterprise Value

IDYA$3.16B

PBLS$2.12B

Price

IDYA$36.11

PBLS$27.48

P/E Ratio

IDYAN/A

PBLSN/A

P/S Ratio

IDYA14.66x

PBLS21,642.36x

EV/Sales

IDYA13.50x

PBLS14,348.08x

EV/EBITDA

IDYA0.00x

PBLS0.00x

P/B Ratio

IDYA3.01x

PBLS3.57x

P/FCF Ratio

IDYAN/A

PBLSN/A

EV/FCF

IDYA-27.76x

PBLS-39.47x

PEG Ratio

IDYAN/A

PBLSN/A

Forward P/E (NTM)

IDYAN/A

PBLSN/A

Forward P/S (NTM)

IDYA59.38x

PBLS581.53x

Revenue (TTM)

IDYA$234M

PBLS$148K

Revenue Growth (YoY)

IDYA3244.7%

PBLSN/A

Forward Rev Growth

IDYA218.2%

PBLS212.5%

Gross Margin (TTM)

IDYA0.0%

PBLS0.0%

Operating Margin (TTM)

IDYA0.0%

PBLS0.0%

EBITDA Margin (TTM)

IDYA-91.5%

PBLS-65635.1%

Net Margin (TTM)

IDYA-74.8%

PBLS-93131.8%

FCF Margin (TTM)

IDYA-48.6%

PBLS-36356.1%

Net Income (TTM)

IDYA$-175M

PBLS$-138M

FCF (TTM)

IDYA$-114M

PBLS$-54M

EPS (TTM)

IDYA-$1.90

PBLS-$1.12

ROE (TTM)

IDYA-1647.0%

PBLS0.0%

ROA (TTM)

IDYA-1511.0%

PBLS0.0%

ROIC (TTM)

IDYA-1647.0%

PBLS0.0%

Cash

IDYA$273M

PBLS$1.09B

Debt

IDYA$0

PBLS$8M

Net Cash/Debt

IDYA$273M

PBLS$1.08B

Current Ratio (TTM)

IDYA10.45x

PBLS17.91x

Quick Ratio (TTM)

IDYA10.21x

PBLS17.83x

Debt/Equity (TTM)

IDYA0.00x

PBLS0.01x

Debt/Assets (TTM)

IDYA0.0%

PBLS0.0%

Interest Coverage (TTM)

IDYAN/A

PBLSN/A

Net Debt/EBITDA (TTM)

IDYA0.00x

PBLS0.00x

Beta

IDYA0.04

PBLS-1.08

52W Performance

IDYA34.5%

PBLS-13.0%

YTD Performance

IDYA6.7%

PBLS-13.0%

% from 52W High

IDYA-15.4%

PBLS-35.3%

% from 52W Low

IDYA38.6%

PBLS12.1%

Asset Turnover (TTM)

IDYA0.20x

PBLS0.00x

FCF Yield (TTM)

IDYA-3.3%

PBLS-1.7%

Earnings Yield (TTM)

IDYA-5.1%

PBLS-4.3%

Dividend Yield (TTM)

IDYAN/A

PBLSN/A

Rule of 40

IDYA3,196.0

PBLS-36,356.1

EV/GP/RG

IDYAN/A

PBLSN/A

Ticker research

View IDYA research View PBLS research

Metric	IDYA IDEAYA Biosciences Inc	PBLS Parabilis Medicines Inc
Market & Valuation
Market Cap	$3.43B	$3.20B
Enterprise Value	$3.16B	$2.12B
Price	$36.11	$27.48
P/E Ratio	N/A	N/A
P/S Ratio	14.66x	21,642.36x
EV/Sales	13.50x	14,348.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.01x	3.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-27.76x	-39.47x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	59.38x	581.53x
Revenue & Growth
Revenue (TTM)	$234M	$148K
Revenue Growth (YoY)	3244.7%	N/A
Forward Rev Growth	218.2%	212.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-91.5%	-65635.1%
Net Margin (TTM)	-74.8%	-93131.8%
FCF Margin (TTM)	-48.6%	-36356.1%
Net Income (TTM)	$-175M	$-138M
FCF (TTM)	$-114M	$-54M
EPS (TTM)	-$1.90	-$1.12
ROE (TTM)	-1647.0%	0.0%
ROA (TTM)	-1511.0%	0.0%
ROIC (TTM)	-1647.0%	0.0%
Financial Health
Cash	$273M	$1.09B
Debt	$0	$8M
Net Cash/Debt	$273M	$1.08B
Current Ratio (TTM)	10.45x	17.91x
Quick Ratio (TTM)	10.21x	17.83x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.04	-1.08
52W Performance	34.5%	-13.0%
YTD Performance	6.7%	-13.0%
% from 52W High	-15.4%	-35.3%
% from 52W Low	38.6%	12.1%
Efficiency & Yields
Asset Turnover (TTM)	0.20x	0.00x
FCF Yield (TTM)	-3.3%	-1.7%
Earnings Yield (TTM)	-5.1%	-4.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	3,196.0	-36,356.1
EV/GP/RG	N/A	N/A
Ticker research	View IDYA research	View PBLS research

Valuation

P/S Ratio

IDYA

14.66x

PBLS

21,642.36x

EV/FCF

PBLS

-39.47x

IDYA

-27.76x

Growth & revenue

Revenue Growth TTM

IDYA

3244.7%

Forward Revenue Growth

IDYA

218.2%

PBLS

212.5%

Profitability & performance

Gross Margin

IDYA

0.0%

PBLS

0.0%

ROE

PBLS

0.0%

IDYA

-1647.0%

FCF Yield %

PBLS

-1.7%

IDYA

-3.3%

52-Week Performance

IDYA

34.5%

PBLS

-13.0%

Detailed metrics comparison

IDYA

IDEAYA Biosciences Inc

PBLS

Parabilis Medicines Inc

Market Cap

IDYA$3.43B

PBLS$3.20B

Enterprise Value

IDYA$3.16B

PBLS$2.12B

Price

IDYA$36.11

PBLS$27.48

P/E Ratio

IDYAN/A

PBLSN/A

P/S Ratio

IDYA14.66x

PBLS21,642.36x

EV/Sales

IDYA13.50x

PBLS14,348.08x

EV/EBITDA

IDYA0.00x

PBLS0.00x

P/B Ratio

IDYA3.01x

PBLS3.57x

P/FCF Ratio

IDYAN/A

PBLSN/A

EV/FCF

IDYA-27.76x

PBLS-39.47x

PEG Ratio

IDYAN/A

PBLSN/A

Forward P/E (NTM)

IDYAN/A

PBLSN/A

Forward P/S (NTM)

IDYA59.38x

PBLS581.53x

Revenue (TTM)

IDYA$234M

PBLS$148K

Revenue Growth (YoY)

IDYA3244.7%

PBLSN/A

Forward Rev Growth

IDYA218.2%

PBLS212.5%

Gross Margin (TTM)

IDYA0.0%

PBLS0.0%

Operating Margin (TTM)

IDYA0.0%

PBLS0.0%

EBITDA Margin (TTM)

IDYA-91.5%

PBLS-65635.1%

Net Margin (TTM)

IDYA-74.8%

PBLS-93131.8%

FCF Margin (TTM)

IDYA-48.6%

PBLS-36356.1%

Net Income (TTM)

IDYA$-175M

PBLS$-138M

FCF (TTM)

IDYA$-114M

PBLS$-54M

EPS (TTM)

IDYA-$1.90

PBLS-$1.12

ROE (TTM)

IDYA-1647.0%

PBLS0.0%

ROA (TTM)

IDYA-1511.0%

PBLS0.0%

ROIC (TTM)

IDYA-1647.0%

PBLS0.0%

Cash

IDYA$273M

PBLS$1.09B

Debt

IDYA$0

PBLS$8M

Net Cash/Debt

IDYA$273M

PBLS$1.08B

Current Ratio (TTM)

IDYA10.45x

PBLS17.91x

Quick Ratio (TTM)

IDYA10.21x

PBLS17.83x

Debt/Equity (TTM)

IDYA0.00x

PBLS0.01x

Debt/Assets (TTM)

IDYA0.0%

PBLS0.0%

Interest Coverage (TTM)

IDYAN/A

PBLSN/A

Net Debt/EBITDA (TTM)

IDYA0.00x

PBLS0.00x

Beta

IDYA0.04

PBLS-1.08

52W Performance

IDYA34.5%

PBLS-13.0%

YTD Performance

IDYA6.7%

PBLS-13.0%

% from 52W High

IDYA-15.4%

PBLS-35.3%

% from 52W Low

IDYA38.6%

PBLS12.1%

Asset Turnover (TTM)

IDYA0.20x

PBLS0.00x

FCF Yield (TTM)

IDYA-3.3%

PBLS-1.7%

Earnings Yield (TTM)

IDYA-5.1%

PBLS-4.3%

Dividend Yield (TTM)

IDYAN/A

PBLSN/A

Rule of 40

IDYA3,196.0

PBLS-36,356.1

EV/GP/RG

IDYAN/A

PBLSN/A

Ticker research

View IDYA research View PBLS research

Metric	IDYA IDEAYA Biosciences Inc	PBLS Parabilis Medicines Inc
Market & Valuation
Market Cap	$3.43B	$3.20B
Enterprise Value	$3.16B	$2.12B
Price	$36.11	$27.48
P/E Ratio	N/A	N/A
P/S Ratio	14.66x	21,642.36x
EV/Sales	13.50x	14,348.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.01x	3.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-27.76x	-39.47x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	59.38x	581.53x
Revenue & Growth
Revenue (TTM)	$234M	$148K
Revenue Growth (YoY)	3244.7%	N/A
Forward Rev Growth	218.2%	212.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-91.5%	-65635.1%
Net Margin (TTM)	-74.8%	-93131.8%
FCF Margin (TTM)	-48.6%	-36356.1%
Net Income (TTM)	$-175M	$-138M
FCF (TTM)	$-114M	$-54M
EPS (TTM)	-$1.90	-$1.12
ROE (TTM)	-1647.0%	0.0%
ROA (TTM)	-1511.0%	0.0%
ROIC (TTM)	-1647.0%	0.0%
Financial Health
Cash	$273M	$1.09B
Debt	$0	$8M
Net Cash/Debt	$273M	$1.08B
Current Ratio (TTM)	10.45x	17.91x
Quick Ratio (TTM)	10.21x	17.83x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.04	-1.08
52W Performance	34.5%	-13.0%
YTD Performance	6.7%	-13.0%
% from 52W High	-15.4%	-35.3%
% from 52W Low	38.6%	12.1%
Efficiency & Yields
Asset Turnover (TTM)	0.20x	0.00x
FCF Yield (TTM)	-3.3%	-1.7%
Earnings Yield (TTM)	-5.1%	-4.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	3,196.0	-36,356.1
EV/GP/RG	N/A	N/A
Ticker research	View IDYA research	View PBLS research